NASDAQ:GTHX
G1 Therapeutics Inc Stock News
$4.27
-0.220 (-4.90%)
At Close: May 06, 2024
Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?
01:40pm, Friday, 28'th Oct 2022 Zacks Investment Research
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?
11:18am, Friday, 28'th Oct 2022
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
01:26pm, Wednesday, 26'th Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it is supporting a Phase 2 investiga
G1 Therapeutics: Catalysts Stacking
03:22pm, Thursday, 20'th Oct 2022
Though no longer having Boehringer as its launch partner, G1 Therapeutics, Inc. posted good sales traction for Cosela. There are several big data releases going into the year-end and next year that ca
G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022
04:30pm, Wednesday, 19'th Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corpor
G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022
12:30pm, Wednesday, 19'th Oct 2022
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporat
Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?
01:40pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?
12:04pm, Wednesday, 12'th Oct 2022
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
10:30am, Monday, 10'th Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:00pm, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
G1 Therapeutics: Building A Franchise
11:46am, Thursday, 29'th Sep 2022
Today, we put G1 Therapeutics, Inc. in the spotlight. The company's main asset is COSELA, a small-molecule, short-acting, inhibitor of cyclin-dependent kinases 4 and 6.
G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference
12:00pm, Wednesday, 07'th Sep 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive O
G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference
08:00am, Wednesday, 07'th Sep 2022
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1's Chief Executive Offic
G1 Therapeutics to Host Virtual R&D Day on September 15, 2022
11:00am, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual R&D D
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:22pm, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exer